Get real-time updates on Telegram
P4
CVE-2026-50034: Blood Glucose Monitoring System (Model No. APG-01 BT) 0x0110_v1.1.0
CVE-2026-50034. CVSS 3.1 base score 6.5 (MEDIUM, Vendor/CNA). EPSS 0.00209 (percentile 0.10996), scored 25-Oct-2026.
Affected technology
Blood Glucose Monitoring System (Model No. APG-01 BT) · 0x0110_v1.1.0
Apollo Pharmacy
Component: Not specified by the source
Attack conditions (Vendor/CNA, CVSS 4.0): Adjacent network · No privileges required · No user interaction required
What an attacker can do
Vendor/CNA’s CVSS 4.0 assessment (base score 7.1/10) rates confidentiality impact as high; integrity and availability impact as none. The description does not specify what an attacker can achieve beyond these rated impacts.
- CWE
- CWE-319
- CCR priority
- 26.1 /100 (P4)
- CVSS 3.1
- 6.5 /10 · CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N · Vendor/CNA
- EPSS
- 0.00209 · percentile 0.1115 · 2026-11-15
- KEV
- no
Provenance
- FIRST EPSS daily exploit-probability · Source record · observed 2026-11-16 06:41:02.068004+00:00 UTC
- NVD CVE API 2.0 · Source record · observed 2026-10-26 06:26:09.176872+00:00 UTC
Stable permalink: https://cybercodered.org/item/cve-cve-2026-50034.html